ClinicalTrials.gg
CompletedNCT02718846Updated Mar 24, 2016

Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets

A Phase 4 interventional study of Meniace and Isobide in Meniere's Disease, sponsored by Alvogen Korea. Completed. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-03-24.

Sponsored by Alvogen Korea (part of Lotus Pharmaceutical Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

A multicenter, randomized, open-label clinical study with a concurrent control group to assess the effectiveness and safety of combined therapy with Isobide solution and Meniace tablets compared to monotherapy with Meniace tablets for patients with Meniere's disease

02

Conditions studied

  • Meniere's Disease

Browse trials for

03

In context

Meniere Disease

74 studies on the registry are indexed under Meniere Disease; 12 are open to participants now.

This study's enrollment of 220 is above the median of 44 across 61 interventional studies indexed under Meniere Disease.

Browse Meniere Disease studies →

Lead sponsor

Alvogen Korea is the lead sponsor of 24 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20 - 80 years of age (in full)
  • A definite Meniere's disease patient according to the diagnostic criteria of AAO-HNS (1995), who has had 2 or more episodes of rotary dizziness lasting more than 20 minutes within the last 3 months (12 weeks) and 1 or more episodes of hearing loss recorded by audiometry, and has tinnitus or ear fullness.
  • For female subjects with the possibility of pregnancy during the study period, a subject whose urine pregnancy test result was negative at the time of the screening visit. A subject in menopause for at least one year, one who has no possibility to become pregnant through surgery, or one who effectively uses an acceptable measure. A subject who definitely agreed to use an adequate contraceptive measure during the clinical study period.

Exclusion criteria

Exclusion Criteria:

  • A patient with the history of ear surgery
  • A patient with the history of endolymphatic sac surgery
  • A patient who used or gentamycin in the eardrum within the last 6 months
  • A patient to whom Isobide was administered within 3 months at the time of screening
  • A patient who has an infection in the ear, paranasal sinuses or the upper airway system
  • A patient who has a disease, other than Meniere's disease, that manifests as repetitive dizziness (e.g. Migrainous vertigo, vertebrobasilar , acoustic neuroma)
  • A patient who has acute intracranial hematoma (If this drug is administered to a patient suspected of having an acute intracranial hematoma without checking for the existence of an intracranial hematoma, bleeding that had been stopped temporarily by brain pressure can occur again when intracranial pressure is reduced. Thus, eliminate the cause of bleeding and administer the drug after ensuring that there are no concerns of rebleeding)
  • A patient with anuria (with urinary output of less than 100 mL/day)
  • A severely dehydrated patient (loss of 10% or more of body weight)
  • A patient with acute pulmonary edema
  • A patient with severe heart failure ( class III or higher)
  • A patient with an adrenal tumor
  • A patient with pheochromocytoma
  • A patient who is hypersensitive to the ingredients of the test and control drugs
  • A patient with a hereditary disease such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption
  • A woman who is pregnant or breastfeeding
  • A patient who is deemed ineligible for this clinical study by the analyst
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    Meniace and Isobide

    co-administration Isobide solution and Meniace tablets

    Drug: Meniace · Drug: Isobide

  • Active comparator
    Meniace

    single administration Meniace tablets

    Drug: Meniace

Interventions

  • DrugMeniace

    6 mg of Meniace tablets were administered 3 times per day after meals

  • an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals

06

What researchers measure

Primary outcomes

  1. the number of vertigo episodes

    Time frame: The difference between the number of vertigo episodes experienced during the 4 weeks before the screening and the number of vertigo episodes during the 4 weeks after administration of the study drug

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2016
First posted
Mar 24, 2016
Start
Feb 2013
Primary completionActual
May 2015
CompletionActual
May 2015
Last update
Mar 24, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02718846
Lead sponsor
Alvogen Korea
Responsible party
Sponsor
First posted
Mar 24, 2016
Start date
Feb 2013
Primary completion
May 2015
Completion
May 2015
Last update
Mar 24, 2016

Study contacts

Won-ho Jeong, Ph.D.
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isosorbide

Start the discussion